Hemostemix’s Commercial-phase 1 longevity treatment highlighted at conference
Hemostemix will present at the Small Cap Growth Virtual Investor Conference on November 19, 2026, with President and CEO Thomas Smeenk scheduled to speak at 12:00 p.m. ET. The post Hemostemix’s Commercial-phase 1 longevity treatment highlighted at conference appeared first on Longevity.Technol

<p>Hemostemix will present at the Small Cap Growth Virtual Investor Conference on November 19, 2026, with President and CEO Thomas Smeenk scheduled to speak at 12:00 p.m. ET.
The post Hemostemix’s Commercial-phase 1 longevity treatment highlighted at conference appeared first on Longevity.Technol</p>